By Sabela Ojea
Moderna secured a $590 million package from the U.S. Health and Human Services Department to accelerate the development of its pandemic influenza shots.
The financial package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the biotechnology company said Friday.
The agreement will also fund the expansion of clinical studies for up to five additional subtypes of pandemic influenza, Moderna added.
The financial support from the federal government comes right before President-elect Donald Trump takes office on Monday, and at a time when Moderna is preparing to advance its mRNA-1018 investigational pandemic influenza vaccine into a Phase 3 trial.
In 2023, Moderna initiated a phase 1/2 study to generate safety and immunogenicity data of the shot in healthy adults ages 18 and older. The trial included vaccine candidates against two avian influenza viruses, H5 and H7.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 17, 2025 16:29 ET (21:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。